EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Feasibility of 5‐fluorouracil and imiquimod for the topical treatment of cervical intraepithelial neoplasias ( CIN ) 2/3

Nerlyne Desravines, Chiu-Hsieh Hsu, Sopan Mohnot, Vikrant Sahasrabuddhe, Margaret House, Edward Sauter, Siobhan O'Connor, Julie E Bauman, H-H Sherry Chow, Lisa Rahangdale iD

International Journal of Gynecology & Obstetrics · 2023

DOI: 10.1002/ijgo.14983 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, 2023. Verfasst von Nerlyne Desravines und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Uterine Cervical Dysplasia, Papillomavirus Infections. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Division of Cancer Prevention, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To determine the feasibility (as measured by tolerability and safety) and efficacy of topical 5‐fluorouracil (5‐FU) and imiquimod for the treatment of cervical intraepithelial neoplasia (CIN) 2/3.

Methods

This pilot prospective study was conducted in women aged 18–45 years with p16+ CIN 2/3. Participants underwent an 8‐week alternating regimen of self‐applied 5% 5‐FU on weeks 1, 3, 5, and 7 and physician‐applied imiquimod on weeks 2, 4, 6, and 8. Adverse events (AEs) were collected by symptom diary and clinical exam. Feasibility was measured by tolerability and safety (AEs) of the study intervention. Tolerability was assessed as the number of participants able to apply 50% or more of the treatment doses. The safety outcome was calculated as the number of participants who experienced “specified AEs” defined as possibly, probably, or definitely related grade 2 or worse AE or grade 1 genital AEs (blisters, ulcerations, or pustules) lasting more than 5 days. The efficacy of the intervention was determined by histology and high‐risk human papillomavirus (hrHPV) testing was done after treatment.

Results

The median age of the 13 participants was 27 ± 2.9 years. Eleven (84.61%) participants applied 50% or more of the treatment. All participants reported grade 1 AEs; 6 (46.15%) reported grade 2 AEs; and 0 reported grade 3/4 AEs. Three (23.08%) participants had specified AEs. Histologic regression to normal or CIN 1 among those completing 50% or more of the treatment doses was observed in 10 (90.91%) participants, and 7 (63.63%) tested negative for hr‐HPV at the end of the study.

Conclusions

Topical treatment for CIN 2/3 with 5‐FU/imiquimod is feasible, with preliminary evidence of efficacy. Topical therapies need further investigation as adjuncts or alternatives to surgical therapy for CIN 2/3.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsUterine Cervical DysplasiaPapillomavirus InfectionsFemaleHumansYoung AdultAdultImiquimodFluorouracilProspective StudiesFeasibility StudiesPapillomaviridae

Stichwörter der Autor:innen

cervical dysplasiacervical intraepithelial neoplasia (CIN) 2/3excision alternativeshigh grade squamous intraepithelial lesion (HSIL)medical managementsurgical treatmenttopical therapy

Substanzen

ImiquimodFluorouracil

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • University of Arizona Cancer Center, Tucson, Arizona, USA.
  • Stony Brook Medicine, Stony Brook, New York, USA.
  • Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, Bethesda, Maryland, USA.
  • Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina, USA.

ORCID-Profile: Lisa Rahangdale

Förderung

  • NCI NIH HHS
  • Division of Cancer Prevention, National Cancer Institute

Zitieren

APA

Desravines, N., Hsu, C. H., Mohnot, S., Sahasrabuddhe, V., House, M., Sauter, E., O'Connor, S., Bauman, J. E., Chow, H. S., & Rahangdale, L. (2023). Feasibility of 5‐fluorouracil and imiquimod for the topical treatment of cervical intraepithelial neoplasias ( CIN ) 2/3. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.14983

Vancouver

Desravines N, Hsu CH, Mohnot S, Sahasrabuddhe V, House M, Sauter E, et al. Feasibility of 5‐fluorouracil and imiquimod for the topical treatment of cervical intraepithelial neoplasias ( CIN ) 2/3. International Journal of Gynecology & Obstetrics. 2023. doi:10.1002/ijgo.14983

BibTeX
@article{Desravines2023,
  author = {Desravines, Nerlyne and Hsu, Chiu-Hsieh and Mohnot, Sopan and Sahasrabuddhe, Vikrant and House, Margaret and Sauter, Edward and O'Connor, Siobhan and Bauman, Julie E and Chow, H-H Sherry and Rahangdale, Lisa},
  title = {Feasibility of 5‐fluorouracil and imiquimod for the topical treatment of cervical intraepithelial neoplasias ( CIN ) 2/3},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2023},
  doi = {10.1002/ijgo.14983}
}
Kostenlos starten →